Shire’s Elaprase Approved For Hunter Syndrome
This article was originally published in The Pink Sheet Daily
Executive Summary
The company plans to launch the orphan enzyme replacement therapy within 30 days.
You may also be interested in...
Shire Collaboration Brings Validation To ArmaGen’s Drug-Delivery Technology
While awaiting finalization of its merger with AbbVie, Shire signed a deal with privately held ArmaGen to license technology that could enable Elaprase to be delivered across the blood-brain barrier. That would enable the Hunter syndrome therapy to treat CNS manifestations of the disease as well as systemic symptoms.
Shire’s Hunter Syndrome Treatment Elaprase Gets European Approval
Enzyme replacement therapy will launch in most countries this year as pricing and reimbursement are negotiated.
Shire’s Hunter Syndrome Treatment Elaprase Gets European Approval
Enzyme replacement therapy will launch in most countries this year as pricing and reimbursement are negotiated.